Review article: Photodynamic therapy and the alimentary tract

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 7, 2001, Pages 899-915

  Selvasekar, C R ^a   Birbeck, N ^b   Mcmillan, T ^c   Wainwright, M ^b   Walker, S J ^a,d  

^a BLACKPOOL VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^c LANCASTER UNIVERSITY   (United Kingdom)

^d BUPA Hospitals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; BENZOPORPHYRIN DERIVATIVE; CARBENE; CHLORINE DERIVATIVE; ETIOPURPURIN; HEMATOPORPHYRIN DERIVATIVE; LU TEX; LUTETIUM TEXAPHYRIN; PHOTOFRIN; PHOTOFRIN II; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ALUMINUM; TIN DERIVATIVE; TOLONIUM CHLORIDE; ZINC;

BARRETT ESOPHAGUS; BILE DUCT CARCINOMA; COLON CARCINOMA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EARLY CANCER; ESOPHAGUS CANCER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; HIGH RISK PATIENT; HUMAN; LIVER CANCER; OROPHARYNX CARCINOMA; PANCREAS CANCER; PATIENT SELECTION; PHOTODYNAMIC THERAPY; PRECANCER; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TISSUE REPAIR; TREATMENT FAILURE; TREATMENT INDICATION; TUMOR NECROSIS; VATER PAPILLA CARCINOMA; GASTROINTESTINAL TUMOR; INFECTION; METHODOLOGY; PHOTOCHEMOTHERAPY; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

GASTROINTESTINAL NEOPLASMS; HUMANS; INFECTION; PHOTOCHEMOTHERAPY; PRECANCEROUS CONDITIONS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0034960734     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.00990.x     Document Type: Review

References (170)

1. Photodynamic therapy in oncology: Mechanisms and clinical use
2. A history of photodynamic therapy
3. Photodynamic therapy in historical perspective
4. Photodynamic therapy
5. Photodynamic therapy
6. Skin photosensitivity and photodestruction of several photodynamic sensitizers
7. Endogenous protoporphyin IX, a clinically useful photosensitizer for photodynamic therapy
8. The treatment of head and neck cancer with photodynamic therapy: Clinical experience
9. Tin ethyl etiopurpurin-induced photodynamic therapy for the treatment of human immunodeficiency virus-associated Kaposi's sarcoma
10. Increased cytotoxicity and phototoxicity in the methylene blue series via chromophore methylation
11. Direct blue dye solutions: Photo properties
12. Liposomemediated delivery of photosensitizers: Localisation of zinc (II)phthalocyanine within implanted tumors after intravenous administration
13. Water soluble aluminium phthalocyanine-polymer conjugates for PDT. Photodynamic activities and pharmacokinetics in tumour bearing mice
14. Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A
15. Texaphyrins: New drugs with diverse clinical applications in radiation and photodynamic therapy
16. Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: A study in patients with (pre) malignant lesions of the oesophagus
17. Identification of singlet oxygen as the cytotoxic agent in photo-inactivation of a murine tumor
18. Definition of type I and type II photosensitized oxidation
19. Photosensitization of mitochondria. Molecular and cellular aspects
20. Ultrastructural changes in the nuclei of human carcinoma cells after photodynamic treatment haematoporphyrin derivative and with tetrasodium-meso-tetra-(4-sulphonatophenyl) porphine
21. Tumour destruction in photodynamic therapy
22. 2 from cells by photodynamic treatment in vitro
23. Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction
24. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages
25. Induction of tumour immunity by photodynamic therapy
26. Carcinoma of the cardia: Role of short-segment Barrett's esophagus and columnar metaplasia
27. The rationale for esophagectomy as an optimum therapy for Barrett's esophagus with high-grade dysplasia
28. Effect of curative versus palliative surgical treatment for stage III pancreatic cancer patients
29. Cancer of the colon and rectum in the West Midlands 1957-81
30. The biology of photodynamic therapy
31. Photodynamic therapy in gastroenterology
32. Gastrointestinal tumours: Let there be light
33. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
34. Endoscopic fluorescence detection of dysplasia in patients with Barrett's esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization
35. Staining in gastrointestinal endoscopy
36. Die Fluoreszenz tierische Gewebe in ultravioletten Licht
37. In vivo fluorescence imaging for tissue diagnostics
38. Hematopophyrin derivative for the detection and management of cancer
39. Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus
40. Hematoporphyrin-derivative fluorescence in malignant neoplasms
41. Intra-abdominal photodynamic therapy: From theory to feasibility
42. Detection of adenocarcinoma in Barrett's oesophagus by means of laser induced fluorescence
43. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy
44. Photodynamic therapy of oral cancer: A review of basic mechanisms and clinical applications
45. Photodynamic therapy: A promising new modality for the treatment of cancer
46. Laser photoradiation therapy of cancer following hematoporphyrin sensitization
47. Photodynamic therapy and the treatment of head and neck neoplasia
48. Photodetection and photodynamic therapy of 'early' squamous cell carcinoma of the pharynx, oesophagus and tracheobronchial tree
49. Hematoporphyrin photodynamic therapy: Is there truly a future in head and neck oncology? Reflections on a 5-year experience
50. Photodynamic therapy for treatment of AIDS-related oral Kaposi's sarcoma
51. The importance of in situ light dosimetry for photodynamic therapy of oral cavity tumors
52. Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity
53. Photodynamic therapy of oral cancer: Photosensitisation with aminolaevulinic acid
54. Photodynamic therapy for cancer of the upper aerodigestive tract using tetra (m-hydroxyphenyl) chlorin
55. Photodynamic therapy using m-THPC for malignant disease in the oral cavity
56. Clinical photodynamic therapy for superficial cancer in the oesophagus and the bronchi: 514 nm compared with 630 nm light irradiation after sensitization with Photofrin II
57. New classification of oesophageal and gastric carcinoma derived from changing patterns in epidemiology
58. Adenocarcinoma of the esophagus with or without Barrett mucosa
59. Barrett's esophagus: Continuing questions and controversy
60. Symptomatic gastro-esophageal reflux as a risk factor for esophageal adenocarcinoma
61. Esophageal cancer: Screening and surveillance. Results of Consensus Conference held at the VIth World Congress of the International Society for Diseases of the Esophagus
62. What is the ideal treatment for early esophageal cancer?
63. Esophageal cancer: Results of an American College of Surgeons patient care evaluation study
64. Quality of life after oesophagectomy: The patients' perspective
65. Review article. Controversy in the therapy of gastro-oesophageal reflux disease - Long-term proton pump inhibition or laparoscopic anti-reflux surgery?
66. Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium
67. Regression of Barrett's esophagus by laser ablation in an anacid environment
68. Photothermal laser ablation of Barrett's esophagus: Endoscopic and histological evidence of squamous re-epithelialisation
69. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery
70. Restoration of the normal squamous lining in Barrett's esophagus by argon plasma coagulation
71. Reconstitution of squamous epithelium in Barrett's oesophagus with endoscopic argon plasma coagulation: A prospective study
72. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: Immediate and mid-term results
73. Barrett's esophagus with severe dysplasia in argon beam therapy
74. Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: Preliminary results
75. Regression of Barrett's esophagus by antireflux surgery and bipolar electrocoagulation
76. Ultrasonic epithelial ablation of the lower esophagus without stricture formation - A new technique for Barrett's ablation
77. Endoscopic resection as local treatment of mucosal cancer of the esophagus
78. Photodynamic therapy for treatment of early adenocarcinoma in Barrett's esophagus
79. Eradication of high-grade dysplasia in columnar-line (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphorphyrin IX
80. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid
81. Current status of photodynamic therapy of Barrett's esophagus
82. Photodynamic therapy for Barrett's esophagus: Follow-up in 100 patients
83. Aminolevulinic acidinduced photodynamic therapy: Safe and effective ablation of dysplasia in Barrett's esophagus
84. Biomarker studies in reversed Barrett's esophagus
85. The histopathology of treated Barrett's esophagus: Squamous reepithelialization after acid suppression and laser and photodynamic therapy
86. The evaluation of submucosal carcinoma of the esophagus as a more advanced carcinoma
87. Resectional surgery in carcinoma of the oesophagus and cardia: What influences long-term survival?
88. Review. Oesophageal cancer: View from East Birmingham
89. Oesophageal cancer: A population-based study of survival after treatment
90. Oesophageal cancer: Outcome of modern surgical management
91. What is the role of radiation-chemotherapy in the radical nonsurgical management of carcinoma of the oesophagus? Upper GI cancer working group of the UK Medical Research Council
92. Preliminary results of haematoporphyrin derivative laser treatment for 13 cases of early oesophageal carcinoma
93. Endoscopic laser treatment of superficial oesophageal cancer
94. Endoscopic photodynamic therapy with hematoporphyrin derivative for primary treatment of gastrointestinal neoplasms in inoperable patients
95. Photodynamic therapy by coloring laser. Can it represent a therapeutic alternative for small epidermoid cancers of the esophagus?
96. Longterm survival after photodynamic therapy for oesophageal cancer
97. Sensitization and photodynamic therapy (PDT) of gastrointestinal tumors with 5-aminolaevulinic acid (ALA) induced protoporphyrin IX (PPIX)
98. Endoscopic treatment of gastrointestinal tumors: Indications and results of laser photocoagulation and photodynamic therapy
99. Photodynamic therapy for esophageal malignancy: A prospective twelve-year study
100. Photodynamic therapy of 168 early stage cancers of the lung and oesophagus: A Japanese multicentre study
101. Photodynamic therapy of early squamous cell carcinoma of the esophagus: A review of 31 cases
102. Photodynamic therapy using 5-aminolaevulinic acid for oesophageal adenocarcinoma associated with Barrett's metaplasia
103. Outcome of patients receiving photodynamic therapy for early esophageal cancer
104. High-dose photoirradiation of esophageal cancers
105. Photodynamic therapy for upper gastrointestinal tumours over the past 10 years
106. Photodynamic therapy and cancer of the esophagus
107. Photodynamic therapy with porfirmer sodium versus thermal ablation with Nd: YAG laser for palliation of esophageal cancer: A multicentre randomized trial
108. Photodynamic therapy for obstructing esophageal cancer: Light dosimetry and randomized comparison with Nd: YAG laser therapy
109. Intraluminal treatment of inoperable oesophageal tumours by intralesional photodynamic therapy with methylene blue
110. Photodynamic therapy of cancer of the oesophagus using systemic aminolevulinic acid and non-laser light source: A phase I/II study
111. Photodynamic therapy for treatment of malignant dysphagia
112. The role of photodynamic therapy (PDT) in inoperable oesophageal cancer
113. Effect of photodynamic therapy in a multimodal approach for advanced carcinoma of the gastro-esophageal junction
114. Photodynamic therapy: A safe and effective treatment for tumour overgrowth in patients with oesophageal cancer and metal stents
115. Photodynamic therapy for tumor ingrowth through an expandable esophageal stent
116. Photodynamic therapy for the treatment of tumour ingrowth in expandable oesophageal stents
117. Early gastric cancer: 46 Cases in surgical department
118. Application of laser in cancer diagnosis and treatment
119. Experiences with photodynamic therapy in early gastric cancer
120. Photodynamic ablation of early cancers of the stomach by means of mTHPC and laser irradiation. Preliminary clinical experience
121. Making light work of early gastric cancer
122. Photodynamic therapy with porphyrin and phthalocyanine sensitisation in normal rat liver
123. Selective accumulation of endogenously produced porphyrins in a liver metastases model in rats
124. Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra (hydroxyphenyl) chlorin (mTHPC) in a rat model
125. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts
126. Nonsurgical therapies for hepatocellular and cholangiocellular carcinoma
127. Mono-L-asartyl chlorin e6 (Npe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model
128. Photodynamic therapy of nonresectable cholangiocarcinoma
129. Photodynamic therapy for the palliative treatment of cholangiocarcinoma
130. Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion
131. Photodynamic therapy for advanced bile duct cancer: Evidence for improved palliation and extended survival
132. Photodynamic therapy of non-resectable cholangiocellular carcinoma
133. Management of patients with carcinoma of the pancreas
134. Carcinoma of the pancreas: Critical analysis of costs, results of resection and the need for standardized reporting
135. Photodynamic therapy in the treatment of pancreatic carcinoma: Dihematoporphyrin ether uptake and photobleaching kinetics
136. Hematoporphyrin derivative uptake and photodynamic therapy in pancreatic carcinoma
137. Selective necrosis in hamster pancreatic tumours using photodynamic therapy with phthalocyanine photosensitization
138. Photodynamic therapy using 5-aminolevulinic acid for experimental pancreatic cancer - Prolonged animal survival
139. Experimental pancreas cancer in the rat treated by photodynamic therapy
140. Distribution and photodynamic effects of meso-tetrahydroxyphenylchlorin (mTHPC) in the pancreas and adjacent tissues in the Syrian golden hamster
141. Photodynamic therapy of transplanted pancreatic cancer model using metatetrahydroxyphenylchlorin (mTHPC)
142. Human pancreatic carcinoma cells are sensitive to photodynamic therapy in vitro and in vivo
143. Photodynamic therapy for malignant tumours of the ampulla of Vater
144. Photodynamic therapy for palliation of unresectable pancreatic cancer
145. Photodynamic therapy in patients with colorectal cancer
146. Photodynamic therapy in the normal rat colon with phthalocyanine sensitisation
147. The contrasting mechanisms of colonic collagen damage between photodynamic therapy and thermal injury
148. Photodynamic therapy for colorectal cancer: A quantitative pilot study
149. Use of photodynamic therapy in the palliation of massive advanced rectal-cancer - Phase I-II study
150. Photodynamic therapy for villous adenomas of the colon and rectum
151. Adjuvant intraoperative photodynamic therapy for colorectal carcinoma: A clinical study
152. Enhancement of photodynamic therapy with 5-amino laevulinic acid induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies
153. Photodynamic therapy for polyps in familial adenomatous polyposis - A pilot study
154. Palliative endoscopic therapy of rectal carcinoma
155. Feasibility of photodynamic therapy using endogenous photosensitization for colon cancer
156. Photodynamically induced effects in colon carcinoma cells (WiDr) by endogenous photosensitizers generated by incubation with 5-aminolaevulinic acid
157. Photo-oxidative killing of human colonic cancer cells using indocyanine green and infrared light
158. Photodynamic therapy. A review
159. Adjuvant intraoperative photodynamic therapy in experimental colorectal cancer using a new photosensitiser
160. Advances in gastrointestinal intervention: The treatment of gastroduodenal and colorectal obstructions with metallic stents
161. Adjuvant intraoperative photodynamic therapy for colorectal cancer
162. Side effects and photosensitization of human tissues after aminolevulinic acid
163. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms -phase-I study
164. Phase-I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors
165. Photodynamic virus inactivation of blood components
166. Photodynamic antimicrobial chemotherapy (PACT)
167. Photolysis of oral bacteria and its potential use in the treatment of caries and peridontal disease
168. The killing of Helicobacter pylori by low power laser light in the presence of a photosensitiser
169. Ex-vivo treatment of gastric Helicobacter infection by photodynamic therapy